MA58653B1 - Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 - Google Patents

Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6

Info

Publication number
MA58653B1
MA58653B1 MA58653A MA58653A MA58653B1 MA 58653 B1 MA58653 B1 MA 58653B1 MA 58653 A MA58653 A MA 58653A MA 58653 A MA58653 A MA 58653A MA 58653 B1 MA58653 B1 MA 58653B1
Authority
MA
Morocco
Prior art keywords
activity
aberrant
interleukin
diseases related
treat diseases
Prior art date
Application number
MA58653A
Other languages
English (en)
French (fr)
Other versions
MA58653A1 (fr
Inventor
Vladimir Evgenievich Nebolsin
Original Assignee
Valenta Intellekt Ltd
Vladimir Evgenievich Nebolsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020121363A external-priority patent/RU2774928C2/ru
Application filed by Valenta Intellekt Ltd, Vladimir Evgenievich Nebolsin filed Critical Valenta Intellekt Ltd
Publication of MA58653A1 publication Critical patent/MA58653A1/fr
Publication of MA58653B1 publication Critical patent/MA58653B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA58653A 2020-06-26 2021-06-18 Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 MA58653B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (ru) 2020-06-26 Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6
PCT/RU2021/050170 WO2021262040A1 (ru) 2020-06-26 2021-06-18 Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6

Publications (2)

Publication Number Publication Date
MA58653A1 MA58653A1 (fr) 2023-07-31
MA58653B1 true MA58653B1 (fr) 2024-02-29

Family

ID=79281595

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58653A MA58653B1 (fr) 2020-06-26 2021-06-18 Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6

Country Status (6)

Country Link
CN (1) CN115803026A (ru)
BR (1) BR112022026356A2 (ru)
CL (1) CL2022003725A1 (ru)
CO (1) CO2023000604A2 (ru)
MA (1) MA58653B1 (ru)
WO (1) WO2021262040A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023249516A1 (ru) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новая кристаллическая форма 1-[2-(1-метилимидазол-4-ил)этил]пергидроазин-2,6-диона и ее фармацевтическое применение

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
UA115431C2 (ru) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Применение глутарилгистамина для лечения заболеваний дыхательных путей
CN102432544B (zh) * 2011-11-17 2014-05-21 天津医科大学 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用
CN110128406B (zh) * 2013-04-12 2021-08-27 制药有限责任公司 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
EA039391B1 (ru) * 2017-09-07 2022-01-21 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
BR112022020814A2 (pt) * 2020-04-13 2022-11-29 Univ Health Network Métodos para tratamento de síndrome de liberação de citocina
CN113582980B (zh) * 2020-04-30 2023-11-24 上海科技大学 基于杂环和戊二酰亚胺骨架的化合物及其应用

Also Published As

Publication number Publication date
WO2021262040A1 (ru) 2021-12-30
CO2023000604A2 (es) 2023-01-26
RU2020121363A3 (ru) 2021-12-27
CL2022003725A1 (es) 2023-05-19
MA58653A1 (fr) 2023-07-31
BR112022026356A2 (pt) 2023-01-17
RU2020121363A (ru) 2021-12-27
CN115803026A (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
MA58653B1 (fr) Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
ATE384724T1 (de) Cyclopropylverbindungen als ccr5 antagonisten
DE60323133D1 (de) Cyclohexylverbindungen als ccr5-antagonisten
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA51627B1 (fr) Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
EP2329842A3 (en) Interleukin-1 inhibitors in the treatment of diseases
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
JP2005532372A5 (ru)
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
PE20050389A1 (es) Compuestos de quinolina y quinoxalina
EA200600480A1 (ru) Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления
MY172303A (en) Compositions and methods of use of phorbol esters
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
EA202191150A1 (ru) Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции
KR20120083356A (ko) Hiv 감염 치료를 위한 n-히드록시벤즈아미드의 유도체